SAMUEL BAYLES: Open Payments
NPI 1043331010 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$823 in 40 payments from 11 companies in 2025. Trend: 2023 $110 · 2024 $214 · 2025 $823
Food & beverage: $823
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $195 |
| Otsuka America Pharmaceutical, Inc. | 8 | $156 |
| Teva Pharmaceuticals USA, Inc. | 2 | $104 |
| Lundbeck LLC | 3 | $90 |
| Janssen Pharmaceuticals, Inc | 3 | $75 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Neurocrine BioSciences, Inc. | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Corium, LLC | 2 | $31 |
Products named: REXULTI, VRAYLAR, AUSTEDO XR, Auvelity, SPRAVATO, INGREZZA, FANAPT, TRINTELLIX.
Industry payments across AR — which companies pay providers there.
